Protagonist Therapeutics (PTGX) Upgraded by Northland Securities to Outperform

Protagonist Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Protagonist Therapeutics Upgraded by Northland Securities on 10-11-21. In a note to investors, the firm issued a new rating of Outperform. The analysts previously had rating of Market Perform.

Shares of Protagonist Therapeutics traded up $17.12 on Monday, reaching $35.36. 45683595 shares of the stock traded hands, compared to its average volume of 1822580. Shares of Protagonist Therapeutics were trading at $35.36 on Monday. The firm’s 50 day moving average is $37.93 and its 200 day moving average is $33.02.Protagonist Therapeutics has a 12 month low of $32.10 and a 12 month high of $50.54. While on yearly highs and lows, Protagonist Therapeutics’s today has traded high as $37.10 and has touched $32.10 on the downward trend. See More Analyst Rating at: RATING

Protagonist Therapeutics Earnings and What to expect: 

Protagonist Therapeutics last posted its earnings data on August 4th, 2021. The reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.14. The company had revenue of $2.27 million for the quarter, compared to the consensus estimate of $5.60 million. Protagonist Therapeutics has generated ($1.92) earnings per share over the last year (($1.92) diluted earnings per share). Earnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.53) to ($2.32) per share. Protagonist Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.53) to ($2.32) per share. The P/E ratio of Protagonist Therapeutics is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Protagonist Therapeutics is -18.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Protagonist Therapeutics has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Protagonist Therapeutics (PTGX) Moving Average Technical Analysis

5 day Moving Average is $21.47 And 5 day price change is $17.61 (99.21%)  with average volume for 5 day average is 9,532,761. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $22.57 and 20 day price change is -$10.03 (-22.10%) and average 20 day moving volume is 4,852,710. 50 day moving average is $37.93  and 50 day price change is -$14.07 ( -28.46%)  and with average volume for 50 days is : 2,121,960. 200 day moving average is $33.02  and 200 day price change is $11.46 (47.95%)  and with average volume for 200 days is : 833,311.

Other owners latest trading in Protagonist Therapeutics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 71,400 which equates to market value of $3.20M and appx 0.00% owners of Protagonist Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 69,830 which equates to market value of $3.13M and appx 0.00% owners of Protagonist Therapeutics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 30,018 which equates to market value of $1.35M and appx 0.00% owners of Protagonist Therapeutics
  • In total Institutional ownership equates to There is no enough data Institutional Ownership Percentage for Protagonist Therapeutics

See More Analyst Rating at: RATING